In support of this notion, B-cell depletion therapy with rituximab in MS leads to a reduced number of T cells in the CSF [11], diminished production of IFN-γ and IL-17, and proliferation of peripheral T cells [5]. Here, IFNG is linked to myeloid sarcoma.